ABCB1 p.Gln475Ala

[switch to full view]
Comments [show]
Publications
PMID: 25016028 [PubMed] Zolnerciks JK et al: "The Q loops of the human multidrug resistance transporter ABCB1 are necessary to couple drug binding to the ATP catalytic cycle."
No. Sentence Comment
74 Plasmids Mutations were introduced into a plasmid encoding human ABCB1 with a C-terminal hexahistidine tag (pCIneo-wtABCB1-6His; ref. 25) by site-directed mutagenesis (QuikChange XL; Stratagene, La Jolla, CA, USA) using the following oligonucleotides: Q132A, 5=-GGTTGCTGCTTACATCGCGGTTTCATTTTGGTGC- 3=; Q132R, 5=-GGTTGCTGCTTACATTCGAGTTTCATTTTG- GTGC-3=; Q475A, 5=-GGGAAATCATTGGTGTGGTGAGTGCT- GAGCCTGTATTGTTTGCCACCACG-3=; Q773A, 5=-GGAATTA- TTTCTTTTATTACATTTTTCCTTGCGGGTTTCACATTTG- GCAAAGCTGG-3=; Q773R, 5=-GGAATTATTTCTTTTATTA- CATTTTTCCTTCGAGGTTTCACATTTGGCAAAGCTGG-3=; Q1118A, 5=-GGGCATCGTGTCCGCGGAACCCATCCTGTTTG-3=; E556Q, 5=-CCCCAAGATCCTCCTGCTTGATCAGGCCACGT- CAGCCTTGG-3=; and E1201Q, 5=-CAGCCTCATATTTTGCTTCT- TGATCAGGCCACGTCAGCTCTGGATAC-3=.
X
ABCB1 p.Gln475Ala 25016028:74:353
status: NEW
Login to comment

121 The Q475A/ Q1118A mutant bound Bodipy-verapamil in the plasma membrane but did not efflux the drug; thus, it accumulated in the plasma membrane of cells expressing the double-Q-loop mutant ABCB1 and also in intracellular compartments (middle panels).
X
ABCB1 p.Gln475Ala 25016028:121:4
status: NEW
Login to comment

132 RESULTS Q loops of the NBDs are essential for drug efflux, but redundancy is built into the molecular mechanism Site-directed mutagenesis was used to introduce glutamine-to-alanine mutations into NBD1 (NBD1-Q475A) and NBD2 (NBD2-Q1118A) and into both NBDs of human ABCB1.
X
ABCB1 p.Gln475Ala 25016028:132:207
status: NEW
Login to comment

142 Cells expressing the single-NBD Q-loop mutants NBD1-Q475A or NBD2-Q1118A, accumulated only low levels of Bodipy-verapamil, similar, but not identical with, those expressing wild-type ABCB1 (Fig. 2C).
X
ABCB1 p.Gln475Ala 25016028:142:52
status: NEW
Login to comment

144 In contrast, cells expressing the double mutant Q475A/Q1118A exhibited no efflux activity and, rather surprisingly and reproducibly, accumulated more Bodipy-verapamil than did the mock-transfected Figure 4.
X
ABCB1 p.Gln475Ala 25016028:144:48
status: NEW
Login to comment

152 (The raw dot plot data also show that Bodipy-verapamil accumulation increased linearly with increasing expression of Q475A/ Q1118A; Supplemental Fig. S1.) Double-Q-loop Q475A/Q1118A mutant is trapped in the inward-open conformation The extracellular loops of human ABCB1 form a discontinuous epitope for the antibody UIC2, characterized by Igor Roninson and colleagues (38) and others (39).
X
ABCB1 p.Gln475Ala 25016028:152:117
status: NEW
X
ABCB1 p.Gln475Ala 25016028:152:169
status: NEW
Login to comment

156 UIC2 reproducibly binds most readily to the Q475A/Q1118A mutant, suggesting that it adopts a conformation consistent with the inward-open state that would be expected to have a high affinity for UIC2.
X
ABCB1 p.Gln475Ala 25016028:156:44
status: NEW
Login to comment

161 In contrast, cells expressing the Q475A/Q1118A mutant accumulated Bodipy-verapamil in both the intracellular compartments and the plasma membrane, where it colocalized with the 4E3 staining (Fig. 3, middle panels).
X
ABCB1 p.Gln475Ala 25016028:161:34
status: NEW
Login to comment

163 The microscopy data are therefore consistent with the UIC2-binding data and suggest that the Q475A/ Q1118A mutant adopts the inward-open conformation, which, in the absence of the 2 Q-loop glutamines, cannot form the NBD-NBD interface and provides additional drug-binding sites in the plasma membrane, which explains the increased accumulation of Bodipy-verapamil in these cells.
X
ABCB1 p.Gln475Ala 25016028:163:93
status: NEW
Login to comment

175 The drug-stimulated ATPase activity of the single-Q-loop mutants was reduced to 9.5 and 8.1% of the wild-type activity for the NBD1-Q475A and NBD2-Q1118A mutants, respectively, and the double mutant was inactive.
X
ABCB1 p.Gln475Ala 25016028:175:132
status: NEW
Login to comment

177 In vitro ATPase data for NBD1-Q475A, NBD2-Q1118A, and wild-type ABCB1 Mutant af9;Nicardipine (50 òe;M) afa;Nicardipine Relative ATPase activity (%)a Km (mM) Vmax (nmol Pi/min/mg) Km (mM) Vmax (nmol Pi/min/mg) Wild type 0.746 afe; 0.22 1691 afe; 228 0.327 afe; 0.49 151 afe; 54 100 Q475A 2.37 afe; 1.64 162 afe; 70*** 0.284 afe; 0.19 8.0 afe; 1.7* 9.5 Q1118A 2.34 afe; 1.39 138 afe; 51*** 0.573 afe; 0.31 8.2 afe; 1.7* 8.1 Data are averages afe; se of c56;4 independent experiments.
X
ABCB1 p.Gln475Ala 25016028:177:30
status: NEW
X
ABCB1 p.Gln475Ala 25016028:177:303
status: NEW
Login to comment

190 A) ECARs of HEK293T cells expressing wild-type (red), NBD1-Q475A (purple), or NBD2-Q1118A (orange) ABCB1 and mock-transfected cells (blue).
X
ABCB1 p.Gln475Ala 25016028:190:59
status: NEW
Login to comment

193 Representative plots from cells expressing wild-type (B), NBD1-Q475A (C), NBD2-Q1118A (D), and Q475A/Q1118A (E) ABCB1.
X
ABCB1 p.Gln475Ala 25016028:193:63
status: NEW
X
ABCB1 p.Gln475Ala 25016028:193:95
status: NEW
Login to comment

197 The V1 for cells expressing the single mutants NBD1-Q475A and NBD2-Q1118A was 1.19and 1.13-fold above basal rates, respectively, corresponding to 50 and 35% of the ATPase activity of wild-type ABCB1.
X
ABCB1 p.Gln475Ala 25016028:197:52
status: NEW
Login to comment

198 No increase in ECAR in the presence of verapamil was detected in cells expressing the Q-loop double mutant Q475A/Q1118A.
X
ABCB1 p.Gln475Ala 25016028:198:107
status: NEW
Login to comment

212 To test whether each verapamil-binding cavity was coupled to the NBDs via a specific Q loop, we combined the single drug cavity mutants TMD1-Q132R and TMD2- Q773R with the NBD Q-loop mutants NBD1-Q475A and NBD2-Q1118A and compared their transport activity (Fig. 6, striped bars) with that of the drug cavity mutants and also the single-and double-Q-loop mutants (Fig. 6, light gray bars; note that the double-Q-loop mutant has a fold difference that is b0d;1 because it provides additional binding sites for Bodipy-verapamil in the membrane).
X
ABCB1 p.Gln475Ala 25016028:212:196
status: NEW
Login to comment

213 The drug cavity mutant TMD1-Q132R combined synergistically with NBD1-Q475A to significantly reduce Bodipy-verapamil export activity to 25% of wild-type activity, but in combination with NBD2-Q1118A, the transporter retained the full level of activity of each single mutant.
X
ABCB1 p.Gln475Ala 25016028:213:69
status: NEW
Login to comment

216 In contrast, TMD2- Q773R combined synergistically with both NBD1-Q475A and NBD2-Q1118A to reduce Bodipy-verapamil export activity to 22 and 34% of the wild-type activity, respectively, showing that the wild-type Q132-lined verapamil-binding cavity of these mutants is coupled to and requires the Q loops of both NBDs to trigger efflux.
X
ABCB1 p.Gln475Ala 25016028:216:65
status: NEW
Login to comment

218 Cytosensor data for NBD1-Q475A, NBD2-Q1118A, Q475A/Q1118A, and wild-type ABCB1 Mutant K1 (òe;M) V1 (fold increase) V1 (% wild-type) K2 (òe;M) V2 (fold increase) Wild type 0.56 afe; 0.03 1.38 afe; 0.01 100 23.05 afe; 3.44 1.09 afe; 0.01 Q475A 0.91 afe; 0.10*** 1.19 afe; 0.02*** 50.2 26.54 afe; 4.84 0.94 afe; 0.02*** Q1118A 0.95 afe; 0.17** 1.13 afe; 0.02*** 35.6 84.81 afe; 30.36*** 0.88 afe; 0.06*** Q475A/Q1118A ND ND ND ND ND Data are averages afe; se of c56;3 independent experiments.
X
ABCB1 p.Gln475Ala 25016028:218:25
status: NEW
X
ABCB1 p.Gln475Ala 25016028:218:45
status: NEW
X
ABCB1 p.Gln475Ala 25016028:218:256
status: NEW
X
ABCB1 p.Gln475Ala 25016028:218:446
status: NEW
Login to comment

253 ߤ Cells expressing the Q475A/Q1118A mutant ABCB1 accumulated more Bodipy-verapamil than did the nontransfected cells, giving a ratio of b0d;1. ns, not significant.
X
ABCB1 p.Gln475Ala 25016028:253:29
status: NEW
Login to comment